PhilippinesLilly's New Drug
Retatrutide delivers 25% weight loss in phase 3 trial. People with type 2 diabetes lost up to 60 pounds.
Global Newsflix 1 min read
Eli Lilly's new weight loss drug, retatrutide, showed substantial weight loss and A1C reduction in a phase 3 trial.
The drug delivered a 25% weight loss. People with type 2 diabetes lost up to 60 pounds.
Retatrutide is a triple agonist.
Key facts
- Retatrutide delivered 25% weight loss in phase 3 trial
- People with type 2 diabetes lost up to 60 pounds
- Retatrutide is a triple agonist
- The drug showed A1C reduction
Three perspectives
Neutral
The trial results are a significant development for people with obesity and type 2 diabetes. The drug's effectiveness will be closely watched. Lilly's work on retatrutide is part of a broader effort to develop new obesity treatments.
Positive
Retatrutide's substantial weight loss and A1C reduction make it a promising treatment option. The drug's effectiveness could improve the lives of people with type 2 diabetes. Lilly's investment in retatrutide reflects the company's commitment to developing innovative treatments.
Negative
The long-term effects of retatrutide are not yet known. The drug's potential side effects and costs are still being studied. More research is needed to fully understand retatrutide's benefits and risks.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.